Premium
Visual outcome following treatment with aflibercept in patients with neovascular age‐related macular degeneration
Author(s) -
Sander B.,
Rasmussen A.,
LundAndersen H.
Publication year - 2015
Publication title -
acta ophthalmologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.534
H-Index - 87
eISSN - 1755-3768
pISSN - 1755-375X
DOI - 10.1111/j.1755-3768.2015.0688
Subject(s) - medicine , aflibercept , visual acuity , macular degeneration , discontinuation , ophthalmology , snellen chart , choroidal neovascularization , retrospective cohort study , surgery , bevacizumab , chemotherapy
Purpose Objective: To evaluate the visual outcome, number of injections and causes for discontinuation of treatment with aflibercept in patients with neovascular age‐related macular degeneration ( nAMD ). Methods Design: Retrospective chart review. Participants: The study included 350 eyes in 350 patients who initiated first time intravitreal therapy for nAMD in 2013–14. Descriptive statistical analysis of change in best‐corrected visual acuity ( BCVA ) from presentation to 3 and 12 months after the first injection. Results The patients’ mean age and visual acuity at baseline were stable at 80 years and 0.24 Snellen. Visual acuity increased significant with a mean of 6 injections; at 3 months to 0.38 Snellen, by 1 year to 0.41 Snellen for patients still in treatment; and to 0.35 Snellen for all patients with last observation carried forward. By 1 year 77% of eyes were still in treatment, 10% had discontinued treatment with no apparent activity of disease and only a mean of 3.3 injections; 10% had discontinued treatment due to low visual acuity, 3% were lost to follw‐up Conclusion Treatment with aflibecept in patients with nAMD showed excellent visual outcome for the majority of eyes treated.